Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-7977 plus ribavirin with or without peginterferon alfa-2a in chronic hepatitis C after prior Gilead HCV studies
NL-OMON39611Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sofosbuvir, ribavirin and peginterferon alfa-2a in hepatitis C virus infection (3 arms), sponsored by Gilead Sciences. Primary endpoints: SVR12 and Adverse events leading to permanent discontinuation. Started Aug 2013; status: active, not recruiting.
02
Drugs
sofosbuvirribavirinpeginterferon alfa-2a
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON39611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39611.